Moncef Slaoui

Moncef Slaoui has spent his career attacking the under-researched diseases that plague the developing world. He already has a cervical-cancer vaccine and a pneumococcal immunization to his credit, and in 2015 he won European approval for the world’s first malaria vaccine, which could limit the spread of a disease that kills more than half a million people a year.   Vaccine development is a passion that’s deeply personal for Slaoui: His sister died from whooping cough, an ­immunizable disease, while they were growing up in Morocco. On his horizon at GlaxoSmithKline: an Ebola vaccine.